Viva Biotech Holdings - Company Profile
Powered by 
All the sales intelligence you need on Viva Biotech Holdings in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Viva Biotech Holdings fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Viva Biotech Holdings.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Viva Biotech Holdings (Viva Biotech) is a contract research, development and manufacturing organization. It offers early-stage structure-based drug research and development to commercial manufacturing to global biopharmaceutical innovators. The company offers structured based drug services, CRO drug research and development services, CRO drug discovery services and CDMO services for small molecule active pharmaceutical ingredients (API) and finished dosage form (FDF), from pre-clinical to commercial supply. It offers its services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. Viva Biotech is headquartered in Shanghai, China.
Headquarters
China
Address
No.735, Ziping Road, Pudong New Area, Shanghai, 201318
Website
www.vivabiotech.com
Telephone
86 21 60893288
No of Employees
2,169
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
1873 (HKG)
Revenue (2024)
$240.6M
-12.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
31.4%
(2024 vs 2023)
Market Cap*
$365.9M
Net Profit Margin (2024)
XYZ
51.0%
(2024 vs 2023)
* As of and is in US$
Viva Biotech Holdings premium industry data and analytics
Products and Services
| Services |
|---|
| Structure-Based Drug Discovery (SBDD) Services |
| CRO Drug Research and Development Services |
| CRO Drug Discovery Services |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | New Products/Services | In May, the company introduced AI-Driven Drug Discovery platform. |
| 2024 | Corporate Changes/Expansions | In December, the company opened a new branch in Boston, the US. |
| 2023 | Contracts/Agreements | In November, the company secured a US$210 million investment from Temasek, Highlight Capital, and True Light. |
Competitor Comparison
| Key Parameters | Viva Biotech Holdings | WuXi AppTec Co Ltd | Pharmaron Beijing Co Ltd | Shanghai Medicilon Inc | Rundo International Pharmaceutical Research & Development Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Shanghai | Shanghai | Beijing | Shanghai | Shanghai |
| State/Province | Shanghai | Shanghai | Beijing | Shanghai | Shanghai |
| No. of Employees | 2,169 | 33,834 | 25,088 | 2,504 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mao Chen Cheney | Chief Executive Officer; Chairman | Executive Board | 2018 | 64 |
| Wu Ying | Executive Vice President; Director | Executive Board | 2018 | 63 |
| Ren Delin | Director | Executive Board | 2018 | 66 |
| Xiong Wei | Chief Financial Officer | Senior Management | 2024 | 42 |
| Susan Chen, Ph.D. | Chief Technology Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer